title: How we will treat chronic myeloid leukemia in 2016.
abstract: Imatinib will become generic in 2016; assuming that its price will decrease precipitously, we expect that the economic forces will change our current practice habits. We reviewed the literature on the current recommendations to treat chronic myeloid leukemia and highlight how we plan to deal with these changes. Specifically, we propose to better characterize patients according to prognostic scores, to allow more attention to those at high risk for disease progression, e.g., 3-month guidelines and BCR/ABL1 message half-time, emphasize compliance by using contemporary technologies, and increase the importance of early monitoring. We hope that our message will open communication between providers, insurance companies and healthcare authorities to offer the best care for our patients.
authors.affiliation: Internal Medicine, University at Buffalo, Buffalo, NY, USA.
authors.forename: Chetasi
authors.initials: C
authors.lastname: Talati
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Evelena P
authors.initials: EP
authors.lastname: Ontiveros
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Griffiths
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Eunice S
authors.initials: ES
authors.lastname: Wang
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address: meir.wetzler@roswellpark.org.
authors.forename: Meir
authors.initials: M
authors.lastname: Wetzler
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
keywords: Chronic myeloid leukemia; Generic; Price of drugs; Tyrosine kinase inhibitors